非病毒性,特定向的CAR-T细胞在B-NHL中获得高安全性和有效性
Jiqin Zhang1, Yongxian Hu2,3,4,5, Jiaxuan Yang6
1Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China. zjqjeremy@163.com.
Nature
|August 31, 2022
概括
这项研究引入了一种新的非病毒CRISPR-Cas9方法,用于制造增强的仿真抗原受体 (CAR) - T细胞. 这些CAR- T细胞在治疗侵袭性B细胞非霍奇金淋巴瘤方面具有很高的安全性和有效性.
科学领域:
- 免疫学
- 遗传学
- 癌症学
背景情况:
- 化学抗原受体 (CAR) - T细胞疗法对血液恶性瘤具有前景,但也有局限性.
- 目前的CAR-T细胞疗法面临挑战,包括潜在的非目标效应和制造复杂性.
研究的目的:
- 开发一种使用CRISPR-Cas9生成CAR-T细胞的新型非病毒基因特异性方法.
- 改造具有PD1集成的增强型CAR-T细胞以提高抗瘤活性.
- 在临床前和临床环境中评估这些新型CAR- T细胞的安全性和有效性.
主要方法:
- 使用CRISPR-Cas9将特定基因的抗CD19CAR卡塞特集成到AAVS1安全港位.
- 开发了一种集成PD1的创新CAR-T细胞结构.
- 在异种移植模型中进行了临床前研究和针对复发性/耐药性侵袭性B细胞淋巴瘤的临床试验 (NCT04213469).
主要成果:
- 已证明非病毒性基因特异性CAR-T细胞生成的可行性.
- 在使用PD1- 集成的CAR- T细胞的异种移植模型中实现了优异的瘤根除.
- 在8名患有侵袭性B细胞非霍奇金淋巴瘤的患者中观察到87. 5%的完全缓解率与持久反应,没有严重的不良事件.
- 在较低的CAR- T细胞输液剂量和高百分比的记忆T细胞下显示有效性.
结论:
- 非病毒性,基因特异性的CAR-T细胞集成,特别是PD1集成,为CAR-T细胞治疗提供了安全有效的创新技术.
- 这种方法增强了抗瘤免疫功能,并为现有的CAR-T细胞疗法提供了有希望的替代方案.
- 这项技术显示出高安全性和有效性,为更广泛的临床应用铺平了道路.
相关概念视频
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Tumor Immunotherapy
644
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
644


